Our expanded panel of cancer cells sensitive to Super-EBS included lung cancer cells carrying distinct RAS mutations, such as A549 (KRAS G12S), H1299 (NRAS Q61K), H2009 (KRAS G12A), as well as EGFR mutations H1975 (EGFR L858R,T790M) and H1650 (E746 A750del), and prostate cancer cells that were androgen-responsive (LNCaP), CRPC cells derived from LNCaP cells (C4-2), their enzalutamide-resistant derivatives (M49F and C4-2R), and CRPC CWR22Rv1 cells that are intrinsically resistant to abiraterone and enzalutamide. The gene discussed is NRAS; the disease is prostate cancer.